The development of diagnostic and therapeutic algorithms is becoming more and more popular in medicine. Their advantage is simplicity which enables wide use in everyday medical practice. The algorithms may have limitations mainly due to simplifications, which not always appear to be helpful in solving complex clinical problems of an individual patient. To serve as a "signpost" in clinical practice, the algorithm should be worked out strictly according to the appropriately inter preted data obtained from reliable, current and published medical evidence. This aim is achieved by clinical practice guidelines, being developed by scientific societies. The present paper deals with diagnostic and therapeutic algorithms in chronic heart failure based on the current clinical practice guidelines.
Working out diagnostic and therapeutic algorithms in medicine is becoming essential on account of that it increases knowledge originating from a considerable number of published reports on clinical trials. The simplicity of such algorithms enables their wide application in everyday medical practice. The algorithms may have limitations mainly due to simplifications, which not always turn out to be useful in solving complex clinical problems of an individual patient. To serve as "signpost" in clinical practice, the scheme ought to be worked out strictly according to the appropriately inter preted data originating from reliable, current and published medical information. This aim is accomplished by clinical practice guidelines, being worked out by scientific societies. It should be emphasized that the algorithms presented in such guidelines need to be one of the components taken into account during clinical decisions, and their application should consider individual assessment of a clinical situation. It is also worth mentioning that the guidelines are prepared mainly based on data coming from large, randomized controlled trials. The nature of those trials, and, in particular, a selective choice of patients, limits their approach towards some groups of patients, particularly the elderly, patients with serious concomitant diseases and multiple risk factors, and females. These are the patients, who are often not enrolled in randomized clinical trials. Those limitations resulting from inter pretation of clinical trials should be
REVIEW ARTICLE
Diagnostic algorithm and therapeutic options in chronic heart failure: updated review of clinical practice guidelines 3) Class III * -there is scientific evidence or general agreement that a method of treatment is useless/ineffective, and sometimes may be harmful.
Gradation of scientific evidence
1) Level A -data derived from multiple randomized clinical trials or from meta-analyses. 2) Level B -data derived from a single randomized clinical trial or several large non-randomized trials. 3) Level C -concurrent opinion of experts and(or) results of small studies; data from retrospective studies and registers.
diagnostic algorithms in CHF Diagnosis of CHF is first of all clinical made based on subjective and objective symptoms. Properly selected tests help confirm the diagnosis, although it should be emphasized that a single, specific test enabling heart failure diagnosis is not available. A definition of heart failure, according to the guidelines of the ESC, underlines the necessity of existence of: 4 1) symptoms of heart failure (at rest or with exertion) and 2) objective (preferably echocardiographic) indications of cardiac dysfunction (systolic and[or] diastolic) at rest 3) and, in case of diagnostic doubts, positive response to treatment directed towards heart failure (HF). Criteria 1 and 2 have to be fulfilled at all events.
Based on such a definition, an appropriate scheme for proper diagnosis of heart failure can be produced (FIGuRE 1) . Interpretation of the symptoms mentioned above in clinical practice may be difficult and it requires taking the patient's age, sex, obesity and concomitant diseases into consideration. It is also well known that the relationship between in symptoms of heart failure and the degree of cardiac dysfunction is weak, and long-term prognosis depends mainly on the magnitude of an increase in symptoms. 4 All guidelines for clinical practice recommend that the classification of the stages of heart failure should be applied according to the NYHA (TABLE 1) .
The rest ECG and the chest X-ray should constitute essential components of initial diagnostics of heart failure (FIGuRE 1). A helpful test, which in the case of correct results virtually enables ruling out heart failure, is the assessment of the B-type natriuretic peptide (BNP, NT-proBNP) level. 1, 4 This test could be particularly useful in primary health care and in hospital emergency units. Other laboratory tests, which are used in initial assessment of a patient being diagnosed for chronic heart failure, include complete blood count, levels of electrolytes, creatinine, glucose, liver enzymes, thyroid hormones in serum and a routine urine analysis.
1,4
Echocardiography is a method of choice to confirm systolic or diastolic heart dysfunction.
particularly considered in the population of Polish patients with heart failure, especially as they may overlap with limited following the doctor's recommendations. Individual conditions of the patients, including their financial situation and high prices they pay for complex pharmacotherapy, influence the way Polish patients follow the rules of long-time therapy in heart failure. Attention should be paid to the fact that the effectiveness of treatment in heart failure is associated with not only of properly applied therapeutic strategies, but also a patient's appropriate behavior and cooperation.
Within the field of treatment for chronic heart failure (CHF) there are four main sets of guidelines developed by 
4
As the Polish Cardiac Society recommended implementation of the European guidelines in Poland, the diagnostic and therapeutic algorithms presented below are compliant with those guidelines. The existing differences between the mentioned recommendations are included in the commentaries (titled "Comparison between the guidelines...").
Guidelines for scientific societies have been divided into recommendation classes, considering the level of scientific evidence supporting the recommendations.
Recommendation classes
1) Class I -there is scientific evidence and(or) general agreement that the analyzed diagnostic procedure/method of treatment is beneficial, useful and effective. 2) Class II -data from studies are ambiguous and(or) there exist divergent opinions concerning the usefulness/effectiveness of a given form of therapy. a) Class IIa -evidence/opinions confirming the usefulness/effectiveness of a method predominate. b) Class IIb -evidence/opinions do not sufficiently confirm the usefulness/effectiveness of a method. Invasive tests (coronary angiography, right heart catheterization with hemo dynamic measurements, endomyocardial bio psy) are not routine tests essential for diagnosis of chronic HF. 1 However, in selected clinical situations, they may be helpful in determining a cause of the disease and introducing appropriate therapy. 1 Treatment algorithm in CHF Treatment in heart failure aims at: preventing the progress of pathophysio logical lesions in the cardiovascular system associated with neurohormone activation, decreasing the intensity of complaints, improving the quality of life and increasing survival rates.
Therapy in patients with CHF due to systolic dysfunction involves non-pharmaco logical measures (guidelines for lifestyle), drug therapy, implanting cardioverter-defibrillators and(or) resynchronization device, mechanical support and surgical treatment. The proposed guidelines for graded non-pharmaco logical, pharmaco logical and surgical treatment for CHF are presented in FIGuRE 2.
Pharmacotherapy Angiotensin-converting enzyme inhibitors (ACEI) ACEI treatment is a cornerstone of heart failure therapy in order to reduce morbidity and mortality. The ACEI therapy should be initiated from class I according to the NYHA. There are several studies related to the role of ACEI in patients with symptomatic chronic heart failure (Cooperative North Scandinavian Enalapril Survival Study, Vasodilator-Heart Failure Trial II and Studies of Left Ventricular Dysfunction -with enalapril) and in patients after myocardial infarction (Survival and Ventricular Enlargement trial -with captopril, Acute Infarction Ramipril Efficacy Study -with ramipril, Trandolapril Cardiac Evaluation Study -with trandolapril). Based on those studies, it has been found that convertase inhibitors reduce mortality risk in CHF by 16%. II-IV) .
Observations have shown that higher doses of β-adrenolytics offer greater clinical benefits. In the Heart failure Bisoprolol Study I study, a 5 mg bisoprolol dose was used and slight improvement, which was not statistically significant, was achieved. Only after the administration of a 10 mg bisoprolol dose in the CIBIS II study, a significant reduction in mortality was showed. However, it should be remembered that reaching the target dose ought to be slow and individualized, and depended on a patient's response. Treatment should be started in patients, who do not display symptoms of hypervolemia, or such symptoms are barely detectabable. Usually, the administration is initiated from quite small doses, which are then gradually increased.
1,2,4 study showed that although treatment with large doses of lisinopril failed to reduce total mortality as compared to small doses of the medication, it reduced the frequency of hospitalization due to exacerbated heart failure. 1,5 Therefore, the ACEI therapy should not be limited only to achieving symptomatic improvement. However, if it is appropriate to use other medications (particularly β-adrenolytics), the ACEI treatment should be intensified (up to a target dose) only after the introduction of such medications.
Class I, level A. Doses of ACEI should be gradually increased to achieve the dosage of effectiveness showed in large controlled clinical trials.
The European guidelines provide a list of ACEI, whose effectiveness has been shown in large controlled clinical trials on HF or left ventricular dysfunction. These medications, whose impact on mortality/frequency of hospitalization in CHF is documented, include: 1 1) captopril (target dose: 25-50 mg 3 times daily) 2) enalapril (target dose: 10 mg twice daily) 3) lisinopril (target dose: 5-20 mg twice daily) 4) ramipril (target dose: 2.5-5 mg twice daily) 5) trandolapril (target dose: 4 mg once daily)
Comparison between the European and American and Canadian guidelines The guidelines are fully unanimous that ACEI constitute a basis for heart failure treatment. The Canadian guidelines, likewise the European ones, list particular medications of that group and their dosage whose effectiveness has been showed in large randomized controlled clinical trials with hard outcomes. The Canadian guidelines clearly prefer and recommend precisely those medications (class I, level A) . 4 Slight differences pertain among others to the recommended dosage of lisinopril once daily. The ACC/AHA guidelines provide the wider spectrum of medications used in CHF treatment. They also take fosinopril, perindopril and chinapril into consideration.
2 The HFSA guidelines do not specify medications or their dosage. 3 This study showed favorable effects of eplerenone in patients early after acute myocardial infarction, with low LVEF (≤40%) and heart failure or diabetes.
3 The Canadian guidelines additionally recommend the use of those medications only in patients with LVEF below 30%. 4
Angiotensin receptor blockers (ARB) It is well known that in patients with symptomatic CHF despite the ACEI treatment, the level of angiotensin II increases. Responsible for this phenomenon are additional enzymatic path ways (e.g. associated with chymase), where angiotensin II is produced. It provides theoretical rationale for the use of ARB, also combined with ACEI. The results of clinical studies that compared the effectiveness of ACEI and ARB were, however, ambiguous (TABLE 2) .
It was a basis for the following recommendations. Comparison between the European and American and Canadian guidelines In respect of use of β-adrenolytics in CHF, the recommendations are generally unanimous. The Canadian guidelines extend only a scope of use of those medications to all patients with LVEF ≤40%, irrespective of the NYHA class. 4 The ACC/AHA and the CCS guidelines recommend bisoprolol, carvedilol, extended release metoprolol succinate (the European guidelines also recommend nebivolol).
Aldosterone receptor antagonists The Randomized Aldactone Evaluation Study showed that in patients with advanced CHF (NYHA III-IV) and LVEF ≤35%, adding spironolactone to the ACEI treatment with a diuretic and digoxin (most patients) significantly reduces mortality.
2,4 Only 10% of patients involved in that study were administered β-adrenolytics.
2,4
The following recommendation has been issued. 1 
Class I, level B. It is recommended to use aldosterone receptor antagonists along with ACEI, β-adrenolytics and diuretics in patients with advanced CHF (NYHA III-IV) due to left ventricular systolic dysfunction (LVSD), because it reduces mortality and morbidity in those patients.
The treatment mentioned above should be provided only in patients, in whom it is possible to monitor closely the renal function and the serum potassium level. The medications recommended in the guidelines are spironolactone and eplerenon in a target dosage of 50 mg daily. 1,2,4 A large recommended target dose of spironolactone is worth mentioning, in particular with other medications having an effect on the renin-angiotensin system (RAS). It is notable that in the Randomized Aldactone Evaluation Study, a mean daily dose of spironolactone was 26 mg.
6 The researchers emphasized in their commentary that severe hyperkalemia had most frequently occurred in patients receiving 50 mg of spironolactone daily. 6 Comparison between the European and American and Canadian guidelines As opposed to the European, Canadian and ACC/AHA guidelines, which unanimously recommend the administration 4 The commentary states it pertains to a reduction in the hospitalization frequency. 4 The American guidelines also do not diversify outcomes and anticipated clinical effects. The HFSA guidelines do not generally differ from the European and Canadian guidelines, and the analyzed combination has a recommendation level of IIa A.
3 The ACC/AHA guidelines significantly differe from the others and limit the clinical significance of ACEI + ARB combination (recommendation level IIb B).
2
The described differences show how diversified could be inter pretations of results of large clinical trials carried out according to the evidence--based medicine (EBM) rules. The recent re-analysis of the DIG trial has shown that in subjects with low plasma digoxin levels (0.5-0.9 ng/ml) not only a reduction in the frequency of hospitalization, but also a significant reduction in mortality can be observed.
9
The administered digoxin doses should probably be reduced to ≤0.125 mg daily. 9
Comparison between the European and American and Canadian guidelines The European and Canadian guidelines list ACEI whose effectiveness has been shown in large controlled clinical trials on heart failure or left ventricular dysfunction. Medications of this group, which in this indication has documented an impact on mortality/hospitalization frequency comprise as follows: 1,4 1) candesartan (target dose: 32 mg) 2) valsartan (target dose: 320 mg). The ACC/AHA guidelines additionally mention losartan as a medication used in cardiac insufficiency with left ventricular systolic dysfunction (target dose: 50-100 mg). 2 The existing divergences in the results of clinical trials on heart failure using ARB (TABLE 2) resulted the guidelines for use of this group of medications, proposed by the Societies (TABLE 3) .
In case of intolerance of ACEI, the existing differences in guidelines of different Societies are few and have no practical significance. Significant divergences appear, however, with the use of ARB in patients with maintaining symptoms of heart failure, despite appropriate treatment with ACEI and β-adrenolytics. In such cases, the ESC guidelines themselves are not coherent in respect of combined administration of ACEI and ARB and the moment of introduction of such therapy in a symptomatic patient. In chart no 4 in the original text of the guidelines (FIGuRE 3 in this paper), adding ARB is recommended in patients who, despite the use of ACEI and β-adrenolytics remain in NYHA functional class III.
1 In Table 22 in the original text of the guidelines, such combination is acceptable already in patients in NYHA class II.
1 This ambiguity is probably associated with the results of 2 large clinical trials which showed the effectiveness of such combination: the Valsartan Heart Failure Trial (Val-HeFT) and the Candesartan in Heart Failure -Added Trial (CHARM-Added trial). 7,8 Both trials involved patients in NYHA functional class II-IV. In the Val-HeFT trial the majority were the patients included in NYHA functional class II (62%), and in the CHARM-Added trial, patients in NYHA class III (73%). 7, 8 Furthermore, in the case of combined use of ACEI and ARB in CHF, the European Rules for diuretic use Diuretics, as compared to other agents used in CHF, cause the quickest symptomatic improvement in patients with signs of pulmonary and(or) systemic congestion. 2 Appropriate use of diuretics influences the effectiveness of therapy with other medications in CHF. Too small doses may cause fluid retention, reduce a response to ACEI and increase the risk of treatment with β-adrenolytics. In turn, too large doses of diuretics may increase the risk of hypotonia, when taking ACEI, and renal insufficiency, when taking ACEI and ARB. 2 The objective of treatment is a reduction in congestion and body weight, usually of 0.5-1 kg daily. 2 Normally, loop diuretics are recommended as first-line agents. 2,4 Furosemide is used most frequently. Many patients respond well to a newer loop diuretic, i.e. torsemide, which has better bio logical availability and longer effects. 2 Thiazide diuretics (when glomerular filtration rate >30-40 ml/min), potassium-saving diuretics or their combinations may also be used.
Potassium level should be preserved definitely above 4 mmol/l. 4, 9, 11 After achieving clinical improvement, it is appropriate to use a diuretic chronically in the smallest dose essential to maintain a patient in a stable condition.
4 Caution is necessary in chronic use of diuretics, because to date no results of larger, randomized clinical trials assessing the outcomes of treatment with this group of medications are available. Diuretics may potentially intensify neurohormone activation, which is increased in CHF. The analysis of patients involved in the DIG trial, which was made using the propensity score in order to reduce the influence of disturbing factors, showed that the CHF patients treated with a diuretic manifested higher total mortality (29%
Comparison between the European and American and
Canadian guidelines The existing divergences between guidelines concern the use of digoxin in patients with preserved sinus rhythm. The HFSA recommendations are similar to the European ones.
3 The ACC/AHA guidelines are similar, and differ only in the assigned lower level of evidence (B).
2 The Canadian guidelines acknowledge recommendations class I with the A level of clinical evidence for this indication. 4 The existing differences are probably associated with the fact that most studies documenting the effectiveness of digoxin come from the period, when other medications (particularly β-adrenolytics and ARB) were used less frequently. They also signify that in drawing up the guidelines for clinical practice "expert opinions" may be substantial in the assessment of significance of scientific evidence. (17% vs. 28%, p <0.001). 13 Similar benefits from the program of multidisciplinary outpatient clinic treatment after hospital discharge were shown by Wierzchowiecki et al. also in the Polish population.
14 The experience of the attending team and frequent control visits in an outpatient clinic (14 days after hospital discharge and at the 3rd, 6th, 9th and 12th months) are thought to have been significant in achieving such positive results. Attention should also be paid to the fact that in case of difficult patients (quick, treatment-resistant progression of heart failure, suspected inflammatory etiology), particularly during the first phase of treatment, a relevant role may be played by a consultation provided by a cardio logist specializing in CHF treatment, in order to expand the diagnostics and tailor therapy to the patient needs.
Lack of satisfactory methods of CHF patient treatment objective assessment is one of the reasons for the limited introduction of the presented guidelines to everyday medical practice. 5, 15 The recent Euro Heart Survey on heart failure, performed by the ESC, demonstrated that only 78% of patients with CHF and LVSD were treated with ACEI.
5 Only 46% of patients were receiving β-adrenolytics, and 29% aldosterone antagonist. 5 In that European study involving 10,701 patients, the doses of administered medications were significantly lower than those used in large controlled clinical trials.
5 Only half of patients who met the inclusion criteria in the SOLVD study, were receiving a target dose of ACEI, and only 10% of patients, who met the criteria for enrollment in the MERIT-HF study, were receiving β-adrenolytics in a recommended dose.
5
An attempt to make the chronic treatment of CHF patients more objective is the inclusion of bio markers, especially BNP/NT-proBNP, in the therapeutic scheme. 16 The recently published, multicenter, randomized STARS-BNP trial confirmed that the CHF treatment with BNP determination may provide greater benefits than the therapy based only on clinical symptoms.
15
In a group of patients, where BNP measurements were additionally used to select the intensity of pharmaco logical treatment, it was found that the use of larger doses of basic medications in CHF therapy (up to 106% of doses recommended for ACEI and 77% for β-adrenolytics) is translated into less frequent occurence of a combined outcome, i.e. deaths and hospitalizations associated with CHF (24% in the BNP group and 52% in the control group; p <0.001).
5 These results are promising, but have to be confirmed by studies involving more numerous groups of patients and based on hard outcomes.
Interventional treatment Cardiac resynchronization therapy (CRT) by means of biventricular stimulation or biventricular stimulation combined with cardioverter-defibrillator.
Class I. Introduction of CRT may be considered in patients with lowered LVEF (≤35%), left
vs. 21%, HR 1.31, p = 0.002) and higher mortality due to HF (9% vs. 6% HR 1.36, p = 0.056). 11 These differences were found irrespective of etiology of heart failure, the NYHA class, ejection fraction and ACEI treatment.
11 However, it should be noted that such retrospective analyses have their limitations, because in everyday practice, patients requiring diuretics or their large doses most frequently demonstrate more advanced stages of CHF. It may have an effect on higher mortality observed in that group.
Selection of a pharmaco logical treatment method
Based on the analyzed European guidelines, we could present a detailed algorithm of pharmacotherapy for symptomatic HF caused by left ventricular systolic dysfunction (FIGuRE 3) .
Selecting a proper dose of medications mentioned in FIGuRE 3, it should be noted that:
1) In case of ACEI and ARB, the dose should be increased gradually up to the recommended one, i.e. the dose used in large, randomized, controlled clinical trials with hard outcomes. The intended dose must be tolerated by a patient. 2) In patients, in whom the hypervolemia signs have been overcome (mainly with ACEI and diuretics), β-adrenolytic therapy should be introduced. The dose ought to be increased gradually up to the target one, determined based on large, controlled clinical trials. 3) Diuretic dosage should be adjusted individually depending on a patient's clinical condition based on intensity of symptoms. The management of a CHF patient according to the presented algorithms should be based on a patient's thorough history concerning intensification of symptoms and toleration of treatment. It is still an activity involving elements of the art of medicine, i.e. subjective assessment made by an attending physician and his/her clinical experience. Taking an appropriate and in-depth history of a patient during control visits plays a considerable role in the optimization of CHF therapy. The role of appropriately selected medical teams in chronic care of CHF patients should also be emphasized. Apart from a cardio logist, such teams need to include a general practitioner, a trained nurse, a clinical psychologist and a physiotherapist. The role of a nurse in this system of multidisciplinary care is crucial. The Argentinean DIAL study showed that in CHF patients randomized to a group, where a routine care was expanded by telephone control of clinical condition, training and modifications in treatment of dehydration carried out by a trained nurse, a 29% reduction in need for hospitalization due to heart failure (p <0.005) was observed. 12 In their findings, Ezekowitz et al. emphasized the role of a cardio logist in chronic care of a CHF patient. In patients who, after hospital discharge, were cared for by a general practitioner and a cardio logist, mortality was lower than in patients attended only by a general practitioner are anticipated to survive in a good functional condition for over one year. 20 Comparison between the European and American and Canadian guidelines In primary prevention of sudden cardiac death (SCD), the American and Canadian guidelines consider patients with lower LVEF in class I recommendations (<30%).
2-4
The European guidelines for heart failure and the HFSA ones do not diversify left ventricular systolic dysfunction in respect of etiology.
1,3 The European recommendations for the prevention of SCD and the ACC/AHA and the CCS for the use of ICD in patients with systolic dysfunction of etiology other than ischemic, are of a lower degree (ESC -I B or IIb B, ACC/AHA -I B; CCS -IIa B or IIb B in patients with LVEF 31-35%). 2, 4, 20 Heart revascularization and related surgeries All guidelines for treatment for CHF concur that in case of patients with symptoms of angina pectoris it is appropriate to consider surgical or percutaneous heart revascularization (class I or IIa and levels of recommendation A or B).
Revascularization in order to improve myocardial contractility or achieve a reduction in CHF symptoms is not recommended in case of no symptoms of angina pectoris (even in the case of hibernated myocardium). 1 Explicitly recommended surgery in CHF patients is excision of the left ventricular aneurism. It is recommended in patients with a large, sectioned off aneurism and signs of heart failure (class I, level C) . 1 Cardiac transplantation is also a recommended method of treatment of final stage heart failure, providing the patients ventricular hypertrophy*, sinus rhythm and synchronization disorders (QRS width ≥120 ms) , with persisting despite optimum pharmaco logical treatment CHF symptoms (III-IV NYHA class) . 1, 17 Receiving CRT-P reduces: 1) clinical symptoms (class I, level A) 1, 17 2) frequency of hospitalization (class I, level A) 1,17 3) mortality (class I, level A) . 17 The use of CRT with cardioverter defibrillator is an accepted alternative method of treatment in such patients, on condition that the expected time of their survival in a good functional condition exceeds 1 year (class I, level B) . 17 The meta analysis of studies concerning resynchronizing therapy (Multisite Stimulation in Cardiomyopathy study; Multicenter InSync Randomized Clinical Evaluation Trial; Multisite Stimulation in Cardiomyopathy Study; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure Trial; Cardiac Resynchronization-Heart Failure Trial) confirmed a favorable influence of the treatment on advanced heart failure outcomes.
18 In comparison with optimal pharmacotherapy, after administering resynchronization therapy, a reduction was found in total mortality by 29% (odds ratio [OR] 0.71, 95% CI 0.57-0.88) and in mortality associated with CHF progression by 38% (OR, 0.62, 95% CI 0.45-0.84).
15
The role of echocardiography in qualifying patients for resynchronization therapy is currently being investigated, because clinical and ECG criteria recommended by the guidelines are not always sufficient. However, recently published results of the PROSPECT study failed to show that currently used ECG manifestations of LV systolic dyssynchrony were useful in qualifying patients for resynchronization therapy. 19 Comparison between the European and American and Canadian guidelines The American, Canadian and European guidelines (for cardiac stimulation and resynchronization) provided the detailed value of LVEF (≤35%), for which the introduction of resynchronization therapy is recommended and assign this form of CHF treatment with the similar class of recommendation (only the HFSA with class IIa). 1-4,17 They, however, do not diversify the anticipated clinical effects and recognize the A level of evidence for this indication. It seems to be justified, especially after drawing the conclusions from the mentioned above meta analysis.
18
Implanted cardioverter-defibrillators (ICd)
Secondary prevention
Class I, level A (to reduce mortality). The implantation of ICD is recommended in patients who survived circulatory arrest caused by ventricular fibrillation, and in patients with poorly hemodynamically tolerated ventricular tachycardia (VT) who undergo optimum pharmacotherapy and Hints on treatment of heart failure with preserved left ventricular ejection fraction coming from clinical or follow-up studies are scarce. Therefore, in the European guidelines we can find the following statement: "There is no unambiguous evidence demonstrating that patients with initially diastolic heart failure benefit from taking individual medications in any way".
1 The American and Canadian guidelines are more detailed in their approach to the methods of treatment of CHF patients with preserved LVSF.
2,4 They are presented in TABLE 4 and they conform with the more general European recommendations.
The paper presents a proposal of the diagnostic and therapeutic scheme in chronic heart failure, worked out based on current guidelines of scientific societies, to be applied in clinical practice. It should be noted that the schemes require periodical updating, because progress in medical knowledge in the field of heart failure is continuous and leads to consistent amendments to the guidelines themselves.
are properly qualified to the surgery (class I, level C). 1 Surgical corrections of serious functional mitral regurgitation in patients with advanced LVSD in order to reduce the CHF symptoms are promising, although they still have a relatively low level of recommendation (class IIb, level C) Restoration and preservation of sinus rhythm in patients with atrial fibrillation to reduce symptoms.
IIb C
Use of β-adrenolytics, ACEI, ARB or calcium antagonists in hypertensive patients may be effective in heart failure symptoms reduction.
Use of digoxin to reduce heart failure symptoms has no sufficient justification. 
